Promore Pharma AB (publ) Interim report January – March 2020
· Net sales amounted to MSEK 0.0 (0.5) MSEK · The operating loss for the period was 7.3 (-5.5) MSEK · Net loss was 7.0 MSEK (-5.5) MSEK, corresponding to a loss per share of SEK 0.19 (-0.27) · Cash flow from operating activities amounted to -15.0 (-4.4) MSEK · Cash and cash equivalents amounted to 45.9 (26.6) MSEK Significant events during the period January - March · The targeted number of 120 patients completing treatment in the HEAL LL-37 Phase IIb clinical trial with ropocamptide was reached Significant events after the reporting period · The company CFO